Earnings Feed
Start Free
Zoetis Inc.·4

Feb 17, 4:22 PM ET

PECK KRISTIN C 4

4 · Zoetis Inc. · Filed Feb 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Zoetis (ZTS) CEO Kristin Peck Exercises Options, Sells Shares

What Happened

  • Kristin C. Peck, CEO of Zoetis Inc., exercised 20,000 stock options on Feb 17, 2026 (exercise price $41.83 per share; total $836,600) and sold a total of 20,000 shares the same day in open-market transactions for aggregate proceeds of approximately $2,540,964.
  • The sales were in two blocks: 9,200 shares at a weighted average price of $126.46 (proceeds $1,163,433) and 10,800 shares at a weighted average price of $127.55 (proceeds $1,377,531). The filing also lists a 20,000-share derivative disposition reported at $0.00 (reported as an exercise/conversion entry).

Key Details

  • Transaction date: Feb 17, 2026.
  • Options exercised: 20,000 shares at $41.83 each (total cost $836,600).
  • Shares sold: 9,200 @ weighted avg $126.46 (range $126.01–$126.98) and 10,800 @ weighted avg $127.55 (range $127.01–$127.56); total proceeds ≈ $2.54M.
  • Notable footnote: Sales were effected under a Rule 10b5-1 trading plan adopted Sep 12, 2025 that allowed sale of up to 20,000 shares upon exercise of options expiring Feb 18, 2026.
  • Vesting/option notes: Footnotes show various option grants and vesting schedules; some referenced options vest over three years and expire ten years after grant.
  • Shares owned after transaction: Not specified in the provided excerpt — see the full Form 4 for updated ownership.
  • Filing timeliness: Form filed Feb 17, 2026 (no late filing indicated in the provided data).

Context

  • This was an exercise of vested options followed by same-day open-market sales under a prearranged 10b5-1 plan. Such transactions are commonly used to exercise expiring options and to sell acquired shares according to a preset plan; they are routine and do not by themselves indicate CEO sentiment about the company.
  • For full details (exact post-transaction holdings, option grant dates/prices, and any tax-withholding or share-surrender mechanics), retail investors should review the complete Form 4 (accession 0001628280-26-008594).

Insider Transaction Report

Form 4
Period: 2026-02-17
Zoetis Inc.ZTS
PECK KRISTIN C
DirectorChief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-17$41.83/sh+20,000$836,600→ 121,337 total
  • Sale

    Common Stock

    [F2]
    2026-02-17$126.46/sh−9,200$1,163,433→ 112,137 total
  • Sale

    Common Stock

    [F3]
    2026-02-17$127.55/sh−10,800$1,377,531→ 101,337 total
  • Exercise/Conversion

    Stock Option

    [F5][F6][F7][F8]
    2026-02-17−20,000→ 249,632 total
    → Common Stock (20,000 underlying)
Holdings

  • Common Stock

    [F4]
    (indirect: By 401(k))
    833.644

  • Stock Option

    [F9][F10][F8]
    Exercise: $156.64→ Common Stock (84,711 underlying)
    84,711

  • Stock Option

    [F9][F11][F8]
    Exercise: $196.14→ Common Stock (62,500 underlying)
    62,500

  • Stock Option

    [F9][F12][F8]
    Exercise: $162.07→ Common Stock (67,148 underlying)
    67,148
Footnotes (12)
  • [F1]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, including for the sale of up to 20,000 shares of Zoetis common stock between January 2, 2026 and February 18, 2026 upon the exercise of certain vested stock options that have an expiration date of February 18, 2026.
  • [F10]One-third of each option will vest on the first, second and third anniversaries of the date of grant, February 19, 2025.
  • [F11]One-third of each option vests on the first, second and third anniversaries of the date of grant, February 6, 2024.
  • [F12]One-third of each option vests on the first, second and third anniversaries of the date of grant, February 8, 2023.
  • [F2]The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.01 to $126.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.01 to $127.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]Represents the common stock equivalents held in the Zoetis Inc. Savings Plan, a 401(k) plan, as of December 31, 2025.
  • [F5]Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan.
  • [F6]32,634 options granted February 14, 2017 at an exercise price of $55.02 per option; 24,642 options granted February 13, 2018 at an exercise price of $73.24 per option; 20,661 options granted February 12, 2019 at an exercise price of $87.51 per option; 55,866 options granted February 11, 2020 at an exercise price of $144.03 per option; 61,078 options granted February 10, 2021 at an exercise price of $160.62 per option; and 54,751 options granted February 8, 2022 at an exercise price of $201.30 per option.
  • [F7]Each option vests on the third anniversary of the date of grant.
  • [F8]Each option expires on the tenth anniversary of the date of grant.
  • [F9]Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
Signature
/s/ Brenda Santuccio, as Attorney-in-Fact|2026-02-17

Documents

1 file
  • 4
    wk-form4_1771363361.xmlPrimary

    FORM 4